Premium
In vitro detection of neutralizing antibodies after treatment of paget's disease of bone with nasal salmon calcitonin
Author(s) -
Grauer Andreas,
Raue Friedhelm,
Schneider HansGerhard,
FrankRaue Karin,
Ziegler Reinhard
Publication year - 1990
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.5650050412
Subject(s) - antibody , medicine , in vivo , neutralizing antibody , clinical significance , immunology , in vitro , calcitonin , biology , microbiology and biotechnology , biochemistry
To elucidate the biologic relevance of circulating sCT antibodies, an in vitro bioassay system for the detection of neutralizing antibodies was developed utilizing the human breast carcinoma cell line T47D. We reasoned that the inhibition of the dose‐dependent cAMP response to sCT in the T47D assay system by anti‐sCT antibodies could be used to determine the in vivo relevance of these antibodies. In this report the clinical course of nine patients with Paget's disease of bone treated with intranasal sCT was correlated with the presence of 125 I‐sCT binding and neutralizing antibodies. Of nine patients treated with 400 IU intranasal sCT per day, seven developed 125 I‐sCT binding antibodies. Of these seven patients, four were found to have neutralizing antibodies; the appearance of the antibodies coincided with the development of resistance. One of these patients was subsequently treated with human calcitonin and revealed a good response to the treatment. There was no clinical resistance observed in the three patients with 125 I‐sCT binding antibodies but no neutralizing antibodies; no resistance was observed in two patients without 125 I‐sCT binding or neutralizing antibodies. We conclude that this new technique to determine the biologic relevance of circulating anti‐sCT antibodies may be an useful adjunct for determining the cause of resistance in patients treated with sCT.